DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.

Author(s): Hantschel O, Rix U, Superti-Furga G

Affiliation(s): CeMM-Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

Publication date & source: 2008-04, Leuk Lymphoma., 49(4):615-9.

Publication type: Review

Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017